Dementia and  N-anisoyl-2-pyrrolidinone?

Dementia and  N-anisoyl-2-pyrrolidinone?

The dementia diseases are of various types, most common is the Alzheimer’s disease, it is found to exist in the greater number of people suffering from dementia. The Alzheimer’s disease does not have any specific causes; it is due to the increase of age. The disease intensifies as the age increases. Dementia with Lewy bodies (DLB) is dementia, another complicated disease, the primary symptoms of the disease is visual hallucinations and “Parkinsonism”. Concentration is one of the main functions of the human brain. The function of concentrating and focusing is carried by the brain. Due to the lack of concentration, you may not be able to focus in any of the work; the lack of focus is one of the symptoms of dementia. The diagnosis may clarify the stage and types of the disease. The disease leads to the lack of concentration and therefore a person may not be able to carry out their regular work easily and independently. There are various methods to improve your concentration though it may not be curable; as you lack it because of the disease. The brain function is affected by the disease

Research supporting its clinical use shows that the supplement enhances cognitive function in impaired individuals along with it increases levels of Brain-Derived Neurotrophic Factor. It also exhibits anxiolytic properties and an increase in social interaction which is very much important for the people for their normal living. The supplement helps in reducing the signs of depression and impulsive behaviours, Exerts a neuroprotective effect. The study on the Aniracetam is carried for its behaviour altering, cognitive enhancement properties and it states that it is a neuroprotective agent for the treatment of Alzheimer’s disease and senile cognitive disorders. Aniracetam is a lipophilic derivative of Piracetam, exhibiting the same effect with an estimation of 3-6x increased potency. It increases cholinergic neurotransmission as a Racetam class of nootropics.  Racetam and an Ampakine are classified into nootropic substance with the cholinergic, dopaminergic, serotonergic and glutamatergic systems internal actions.

The Clinical uses of Racetams

It helps in improving and slowing deterioration in senile dementia such as Alzheimer diseases. Apart from alertness, cooperation, socialization, and IQ in elderly patients, it improves reading capacity and accuracy in dyslexia, as well as the speed of reading, writing, and spelling. Boosting the performance related to thinking, talking, observing and reading, the mental performance in ageing, non-deteriorated individuals suffering only from memory loss.

The function of Aniracetam

The first neurotransmitter affected by N-anisoyl-2-pyrrolidinone is Acetylcholine, it is a brain chemical which is involved in a number of cognitive processes including memory, learning capacity, attention span, mental energy. The nootropic drug connects to the Acetylcholine receptor sites and inhibits their desensitization, promoting greater acetylcholine release at the synapses. AMPA receptors are involved in the fast excitatory transmission of your synapses. Aniracetam binds to these receptor sites when they are inactive and creating a higher influential glutamate transmission.  In a study, aniracetam was found to facilitate dopaminergic signalling via dopamine release and dopamine D2 receptor activation through stimulation of excitatory nicotinic acetylcholine receptors.